Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of 4.50% is 43% below its 5-year average of 7.83%, around the middle of its 5-year range (0.22%–12.32%).
44.20% below its 12-month average of 8.06%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): 1.74%.
RETURN ON ASSETS (ROA)
4.50%
RETURN ON ASSETS (ROA) AVG TTM
8.06%
RETURN ON ASSETS (ROA) AVG 3Y
9.38%
RETURN ON ASSETS (ROA) AVG 5Y
7.83%
RETURN ON ASSETS (ROA) AVG 10Y
5.18%
RETURN ON ASSETS (ROA) AVG 15Y
4.23%
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-44.20%
CURRENT VS 3Y AVG
-52.05%
CURRENT VS 5Y AVG
-42.57%
CURRENT VS 10Y AVG
-13.11%
CURRENT VS 15Y AVG
+6.43%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-24.95%
median of 438 covered companies
CURRENT VS SECTOR MEDIAN
+118.04%
vs the sector median at left
Amphastar Pharmaceuticals, Inc.
Market Cap
$1.12B
Return on Assets (ROA)
4.50%
TTM Avg
8.06%
3Y Avg
9.38%
5Y Avg
7.83%
Market Cap
$1.12B
Return on Assets (ROA)
-3.46%
TTM Avg
-0.37%
3Y Avg
-7.11%
5Y Avg
-6.26%
Market Cap
$1.14B
Return on Assets (ROA)
-36.19%
TTM Avg
-21.98%
3Y Avg
-157.70%
5Y Avg
-157.70%
Market Cap
$1.14B
Return on Assets (ROA)
-8.93%
TTM Avg
-2.89%
3Y Avg
-5.64%
5Y Avg
-7.78%
Market Cap
$1.16B
Return on Assets (ROA)
0.69%
TTM Avg
1.67%
3Y Avg
0.18%
5Y Avg
-3.47%
Market Cap
$1.05B
Return on Assets (ROA)
-6.43%
TTM Avg
-17.46%
3Y Avg
-82.63%
5Y Avg
-55.94%
Market Cap
$1.20B
Return on Assets (ROA)
-57.23%
TTM Avg
-57.23%
3Y Avg
-57.23%
5Y Avg
-57.23%
Market Cap
$1.04B
Return on Assets (ROA)
-43.17%
TTM Avg
-16.38%
3Y Avg
-11.13%
5Y Avg
-30.16%
Market Cap
$1.03B
Return on Assets (ROA)
-0.20%
TTM Avg
-7.25%
3Y Avg
-2.02%
5Y Avg
0.01%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Amphastar Pharmaceuticals, Inc. (AMPH) | $1.12B | 4.50% | 8.06% | 9.38% | 7.83% |
| Castle Biosciences, Inc. (CSTL)vs › | $1.12B | -3.46% | -0.37% | -7.11% | -6.26% |
| Bicara Therapeutics Inc. Common Stock (BCAX)vs › | $1.14B | -36.19% | -21.98% | -157.70% | -157.70% |
| Harrow Health, Inc. (HROW)vs › | $1.14B | -8.93% | -2.89% | -5.64% | -7.78% |
| GoodRx Holdings, Inc. (GDRX)vs › | $1.16B | 0.69% | 1.67% | 0.18% | -3.47% |
| Teladoc Health, Inc. (TDOC)vs › | $1.05B | -6.43% | -17.46% | -82.63% | -55.94% |
| Avalyn Pharma Inc. Common Stock (AVLN)vs › | $1.20B | -57.23% | -57.23% | -57.23% | -57.23% |
| Immatics N.V. (IMTX)vs › | $1.04B | -43.17% | -16.38% | -11.13% | -30.16% |
| Integra LifeSciences Holdings Corporation (IART)vs › | $1.03B | -0.20% | -7.25% | -2.02% | 0.01% |
| Cronos Group Inc. (CRON)vs › | $1.21B | 5.91% | 1.36% | -4.42% | -8.30% |
ROA
4.5%
ROE
10.2%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 6.02% |
| 2024-12-31 | 10.11% |
| 2023-12-31 | 9.09% |
| 2022-12-31 | 12.32% |
| 2021-12-31 | 9.25% |
| 2020-12-31 | 0.22% |
| 2019-12-31 | 8.34% |
| 2018-12-31 | -1.12% |
| 2017-12-31 | 0.99% |
| 2016-12-31 | 2.46% |
| 2015-12-31 | -0.71% |
| 2014-12-31 | -2.75% |
| 2013-12-31 | 3.50% |
| 2012-12-31 | 5.70% |
| 2011-12-31 | 0.00% |
